The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Amyloidosis Sessions: Highlights from ASH 2024
Welcome to The Amyloidosis Sessions brought to you by the Video Journal of Hematology and Hematological Oncology (VJHemOnc). This exclusive session features experts Vaishali Sanchorawala and Ashutosh Wechalekar, who discuss their highlights in amyloidosis presented at the 2024 ASH Annual Meeting and Exposition. The experts cover several topics, including updates from the ANDROMEDA trial (NCT03201965), the risk stratification of patients with light chain (AL) amyloidosis, the value of measurable residual disease (MRD), and potential advances with CAR T-cell therapy in this disease setting.
